Published on October 25, 2017
The first CAR-T cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell therapy, an approach that uses the body’s own system to fight the disease. Find out why Dr. Deininger calls this approval “revolutionary.”
Your site is AWESOME! Thank you all so much for this incredible resource to families who are in crisis/affected by cancer.